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Abstract
Joint analysis of longitudinal and survival data has received increasing atten-
tion in the recent years, especially for analyzing cancer and AIDS data. As both
repeated measurements (longitudinal) and time-to-event (survival) outcomes are
observed in an individual, a joint modeling is more appropriate because it takes
into account the dependence between the two types of responses, which are often
analyzed separately. We propose a Bayesian hierarchical model for jointly modeling
longitudinal and survival data considering functional time and spatial frailty effects,
respectively. That is, the proposed model deals with nonlinear longitudinal effects
and spatial survival effects accounting for the unobserved heterogeneity among indi-
viduals living in the same region. This joint approach is applied to a cohort study of
patients with HIV/AIDS in Brazil during the years 2002–2006. Our Bayesian joint
model presents considerable improvements in the estimation of survival times of the
Brazilian HIV/AIDS patients when compared with those ones obtained through a
separate survival model and shows that the spatial risk of death is the same across
the different Brazilian states.
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1 Introduction
In several biomedical studies, longitudinal and survival data are collected simultaneously
but often separately analyzed. A joint analysis of these type of data has some advantages
compared to the corresponding separate data analysis (Tsiatis and Davidian [1]). Concep-
tually a joint model assumes that a latent structure links both kinds of data. For instance,
in clinical trials to evaluate new treatments in patients with the human immunodeficiency
virus (HIV) the number of CD4+ T lymphocyte (CD4 counts for short) has been pro-
posed as a surrogate biomarker (Tsiatis et al. [2]). In a blood transfusion safety study
involving AIDS-free survival times and longitudinal CD4 counts, Faucett and Thomas [3]
concluded that the relative risk of AIDS was larger than those ones obtained by analysis
of the component sub-models separately. Most joint models have been applied in AIDS
and cancer contexts (see e.g. [4, 5, 6, 7]), but also in environmental and health studies,
e.g., radiation dose level [8], psychiatric disorder scale [9] and quality-of-life index [10].
Apart from incorporating the repeated measures into the survival model by regarding
them as time-dependent covariates measured with error [8] there are other approaches to
joint modeling. Namely link longitudinal and time-to-event outcomes via a subject-level
[2] or a cluster-level [11] random effects. Another approach is to consider an unknown
time-varying latent variable to link the two outcomes [4, 9]. Tsiatis and Davidian [1] is
a comprehensive review of these models prior to 2004. Chapter 7 in Ibrahim et al. [12]
devotes special attention to the subject, summarizing some of the most important joint
models, including both Bayesian and frequentist perspectives. Rizopoulos published a
book on joint models for longitudinal and time-to-event data with applications in R [13],
and two R packages on this matter (JM [14] and JMbayes [15]), which are not able to
work with structured spatial components. Recently, Gould et al. [16] reviewed currently
available methods and software tools for carrying out joint analysis, including issues of
implementation and interpretation.
Although many works have been published on joint analysis, it has not yet been routinely
applied to the analysis of individuals who share an unobserved heterogeneity within a
local health region (spatial frailty), as well as other functional effects of the longitudinal
outcome. Usually, survival models with frailties assume independent random effects but
we here consider that those effects are spatially correlated representing clusters of indi-
viduals living in a given region (see Chapter 9 in Banerjee et al. [17]). In this paper we
focus on spatial survival analysis jointly modeled with a longitudinal biomarker that can
have a functional effect (e.g. polynomial) providing more flexibility in the longitudinal
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trajectories. The model has a fully Bayesian approach being inspired in Henderson et
al. [9] who proposed a likelihood-based joint model using the EM algorithm, linking the
longitudinal and survival responses with a zero-mean latent bivariate Gaussian process
and in Guo and Carlin [6] who addressed the problem of joint analysis without a spa-
tial frailty by proposing a Bayesian hierarchical model using Markov chain Monte Carlo
(MCMC) methods. Notice that models linked by random effects, which induces correla-
tion between the longitudinal and survival components, are more friendly to implement
via MCMC methods than via EM algorithm. However they are time consuming due to
the high number of parameters.
The remainder of this paper evolves as follows. In Section 2 we describe the HIV/AIDS
data set that motivated our joint modeling approach, whereas Section 3 outlines the spatial
joint model with longitudinal and survival components. Section 4 discusses the related
Bayesian model assessment by employing Cox-Snell residuals and multiple-imputation-
based residuals, random visiting times and prediction of future values. In Section 5 we
conduct an analysis of the HIV/AIDS data applying the proposed joint model, including
residuals and predictions. Concluding remarks and discussion of important related issues
are presented in Section 6. Finally some additional notes on sensitivity and predictive
performance analysis as well as additional figures and tables are given in Supplementary
Material (SuppMat).
2 The HIV/AIDS data
Brazilian National AIDS Program generated three major electronic databases [18]: (i)
SINAN-AIDS (Information System for Notifiable Diseases of AIDS Cases) which is the
most important electronic AIDS surveillance database, with all cases reported since 1980;
(ii) SISCEL (Laboratory Test Control System) designed to monitor laboratory tests, such
as CD4 counts and viral load tests for HIV/AIDS patients followed in the public health
sector since 2002; (iii) SICLOM (System for Logistic Control of Drugs) developed to
control the logistic for the AIDS treatment deliveries; it shares the patients list with
SISCEL since 2002. These three databases have been previously combined in a single
database with both HIV and AIDS cases using a process called record linkage, which
was adopted by the Surveillance Unit of the Brazilian National AIDS Program [18]. This
linkage strategy has been increasingly used in AIDS surveillance and research [19] to verify
under-reporting of cases and eliminate the duplicated ones. In Brazil, that procedure has
improved the quality of HIV/AIDS data information [18]. Notice that 2002–2006 can be
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considered as the first period with substantial information on both HIV/AIDS survival
and CD4 exams, where 88 laboratories located in all twenty-seven Brazilian states were
using SISCEL, covering 90% of all CD4 and viral load exams carried out by the public
health sector. Cases diagnosed before 2002 were excluded because personal identifiers
were not available in the mortality database for the entire country before that date [18].
For institutional reasons, we had access only to a simple random sample of the combined
database, henceforth called HIV/AIDS data. The related information includes N = 4,653
patients, corresponding to 10% of the total number of diagnosed individuals during the
period 2002–2006. The time-to-event after HIV/AIDS diagnosis is defined as the time
period, in years, between the date of diagnosis and the date of death (available if death
happened before December 31st 2006, and censored otherwise). A longitudinal measure
of immunologic and virologic status (CD4 counts) was collected. Apart from those two
outcomes, the explanatory variables included were: (i) age, coded 0 (15–49 years) and 1
(at least 50 years); (ii) gender, coded 0 (female) and 1 (male); (iii) previous opportunistic
infection (PrevOI) at study entry, coded 0 (without PrevOI) and 1 (with PrevOI); (iv)
patient’s Brazilian state of residence (state). As referred by Souza-Jr et al. [20], the age
cut-off was chosen based on the Ministry of Health recommendations, as the group aged
over 50 showed a higher proportion of delayed initiation of the therapy when compared
to the population group aged 15-49 years.
The CD4 counts distribution by gender, age and PrevOI indicates a high degree of skew-
ness toward high CD4 counts (Figure 1 – SuppMat), suggesting a power transformation
for that outcome to achieve the normality (see Taylor and Law [21] for a discussion about
the power transformation of CD4 counts). There were about 7% of dead patients, 88%
were between 15 and 49 years, 60% of patients were males of whom 8% died, and 61%
had no previous infection, whereas 6.7% lived in the Central-West region, 11.5% in the
Northeast, 4.8% in the North, 60% in the Southeast region and 16.7% in the South (Table
5 – SuppMat). The median of the CD4 counts was 245 cells/mm3 (226 cells/mm3 for
males and 263 cells/mm3 for females). All patients made on average 4.62 CD4 exams
resulting in a total of 21,508 observations (Figure 2 – SuppMat).
3 Joint modeling framework
Suppose a set of N subjects coming from K regions with nk patients each,
∑K
k=1 nk = N ,
followed over a certain time period for which were collected both longitudinal and survival
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response variables, as well as a set of explanatory variables. Our goal is to understand
the relation of all these variables modeling the true value of the longitudinal outcome at
time point t, y∗ik(t), and the survival component, T
∗
ik, to a certain endpoint for the ith
patient living in the kth region, i= 1, . . . , nk, k = 1, . . . , K. Time-to-event, T
∗
ik, may be
subject to the usual right censoring mechanism and then only the minimum, Tik, of the
time-to-event and censoring time, Cik, is observed, Tik ≡ min(T ∗ik, Cik). We define the
event indicator as δik, where δik = 1 indicates a failure (T
∗
ik ≤ Cik) and δik = 0 indicates
a right censored observation (T ∗ik > Cik).
Longitudinal outcomes are collected on each subject intermittently at some set of times
{tikj ≤ Tik : i = 1, . . . , nk; k = 1, . . . , K; j = 1, . . . , nik} producing the observed vector
yik = (yik1, . . . , yiknik)
⊤, where yikj ≡ yik(tikj) and nik is the repeated measurements
number of the longitudinal outcome for the ikth individual. Note that the observed value
of the longitudinal response at time tikj, yik(tikj), is the true value with error, i.e.
yik(tikj) = y
∗
ik(tikj) + eik(tikj), (1)
where eik(tikj) ≡ eikj is an intra-subject error, j=1, . . . , nik, i=1, . . . , nk and k=1, . . . , K.
Now, as in Henderson et al. [9], and Guo and Carlin [6], we introduce the joint model
starting with the longitudinal and survival components separately.
3.1 Longitudinal component
We postulate a mixed effects model to describe the longitudinal latent process in (1),
y∗ik(tikj), by specifying it as a function of “fixed” and random effects,
y∗ik(tikj) = µik(tikj) +Wik(tikj), (2)
where µik(tikj) is the “fixed” component that can be described by a curve (polynomial)
growth model, providing more flexibility in the longitudinal trajectories, and Wik(tikj) is
the random component for which can be considered a zero mean latent Gaussian process.
Specifically we will define: µik(tikj) = x
⊤
1ik(tikj)β1, where β1 is the population parameters
vector (fixed effects) related to a covariate vector x1ik(tikj), and Wik(tikj) = z
⊤
1ik(tikj)bik,
where z1ik(tikj) denotes a design vector corresponding to a random effects vector, bik,
i=1, . . . , nk, k=1, . . . , K, j=1, . . . , nik.
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3.2 Spatial survival component
A traditional framework to link a longitudinal process to a disease outcome is the relative
risk model (Kalbfleisch and Prentice [22]),
hik(t | Y∗ik(t),x2ik) ≡ lim
dt→0
P{t ≤ T ∗ik < t+ dt | T ∗ik ≥ t,Y∗ik(t),x2ik}dt−1
= h0(t) exp{β⊤2 x2ik + γ y∗ik(t)}, (3)
where Y∗ik(t) = {y∗ik(u), 0 ≤ u < t} denotes the history of the true and unobserved
longitudinal process up to time point t, β2 is the vector of regression parameters associated
to the vector of covariates x2ik, h0(t) is the baseline risk function and γ quantifies the effect
of the underlying longitudinal outcome to the risk for an event. For instance, it measures
the effect of CD4 counts to the risk of death in the HIV/AIDS data.
A common criticism to the model (3) has been its dependence regarding the history of the
longitudinal biomarker up to time t, Y∗(t). First, it can include improper extrapolation
beyond the range of the longitudinal measurements because the last registration of the
biomarker may be quite temporally distanced from the moment of failure. Second, it
is not obvious that the imputed value for the longitudinal variable is the more relevant
biological summary. For example, changes in the slope of the trajectory may be more
predictive of patient’s survival time than the current value of the marker.
Alternatively, one can induce the association between the survival and longitudinal pro-
cesses by using only the Gaussian process Wik(t) in (2). In addition, assuming a Weibull
baseline hazard function, i.e., h0(t) = at
a−1, model (3) can be replaced by
hik(t) = at
a−1 exp{x⊤2ik(t)β2 + γ⊤g(Wik(t))}, (4)
where g(·) is a link function specifying which components of the longitudinal process are
related to hik(.), β2 represents the vector of regression coefficients associated with the
vector of the possibly time-dependent explanatory variables, x2ik(t) (may coincide with
x1ik(t)); γ denotes a vector of parameters which measure the association between the
survival and longitudinal components, and a > 0 is the shape parameter of the Weibull
distribution, denoted by W(a, λ), being λ the exp(·) function in (4).
Sometimes individuals are clustered in a hierarchical structure such that subjects within
the same cluster share a common frailty, for example, the incidence of some diseases is
lower or higher in regions with better health services or more environmental problems,
respectively. We consider here a special case of the frailty survival model, introducing
region-specific random effects exhibiting spatial dependence (Banerjee et al. [17]). In
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order to accommodate this spatial extra-variation we extend our survival model by adding
appropriate random effects into its hazard function (4). Let Qk be the spatial effect of
latent risk factors related to the kth region, k=1, . . . , K. Thus, the spatial survival model
is defined by
hik(t) = at
a−1 exp{x⊤2ik(t)β2 + γ⊤g(Wik(t)) +Qk}, (5)
where Qk captures the residual or unexplained log-relative risk of an event (e.g. death)
in the kth region.
The HIV/AIDS data described in Section 2 have well-defined spatial boundaries associated
with the residence geographic regions (Brazilian states) which is a typical example of
areal or lattice data. In addition, we believe that there exists a “neighborhood effect”,
where neighboring locations have a similar risk-of-death, and also a “grouping effect”,
where subjects living in the same region are assumed to have identical risk. We will
develop this matter more deeply in Subsection 3.4, namely discussing the appropriate
prior distributions for Qk.
The introduction of the spatial random effects in (5) serves three main purposes: (i)
capturing the unexplained risk-of-death in each of the 27 Brazilian states; (ii) mapping
the spatial risk-of-death for an epidemiological interpretation purpose (Figure 2) and (iii)
investigate the need to include spatially varying covariates (vide Subsection 5.2).
3.3 Likelihood
We propose a spatial joint model assuming that the longitudinal (2) and spatial survival
(5) components share the same set of time-independent random effects, bik. We will define
Wik(t) = z
⊤
1ik(t) bik (6)
and
g(Wik(t)) = Z2ik(t) bik, (7)
where z1ik(t) and Z2ik(t) are appropriate design vector and matrix, respectively. For
instance, considering bik = (b1ik, b2ik)
⊤, γ = (γ1, γ2)
⊤ and Z2ik(t) an identity matrix, we
may have z⊤1ik(t) bik = b1ik + b2ik t and γ
⊤Z2ik(t) bik = γ1b1ik + γ2b2ik. This specification
allows different subjects to have different baseline repeated measures and different time
trends for longitudinal responses during the follow-up. Note that γ = 0 means a separated
analysis of the longitudinal and survival data.
For the spatial joint model hereafter cited by joint model (6)-(7), we are assuming that
the repeated measures and time-to-event are independent given the random effects and
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the covariates of interest. We also assume a normal distribution, N (0, σ2), for the mea-
surement errors, eikj. Due to the significant separation in time between observations,
correlation among residuals over time is assumed to be negligible, so the error eikj be-
longs to a sequence of independent and identically distributed random variables assumed
as independent of the random effects, bik. Rizopoulos et al. [23] remarked that as the
number of repeated measurements per subject increases, a misspecification of the random
effects distribution has a minimal effect in the parameter estimates and their standard
errors. Under a matrix approach, we assume that bik|Σ ∼ Np(0,Σ). The structure of
the p × p covariance matrix, Σ, describes the association between repeated measures of
the observed longitudinal data. Because bik links both the longitudinal and survival pro-
cesses it accounts for both the association between the two model components and the
correlation between the repeated measurements in the longitudinal process.
Let θ be a generic vector of all parameters of the spatial joint model and L(θ|D) the related
likelihood function, where D = {yik, Tik, δik; i = 1, . . . , nk, k = 1, . . . , K} represents the
observed data, composed of the survival (Tik, δik) and longitudinal yik = (yik1, . . . , yiknik)
⊤
components, whose elements are observations from the normal distribution, N (y∗ikj, σ2).
Covariates in D have been suppressed to facilitate the exposition. Lik(θ|D) denotes the
contribution of the ikth individual to the likelihood, L(θ|D), defined as
Lik(θ|D) = L1ik(bik,β1, σ2|D)× L2ik(bik,β2,γ, Qk|D), (8)
where L1ik(·|D) and L2ik(·|D) denote the corresponding contributions for the longitudinal
and survival components, respectively. The related longitudinal contribution, L1ik(bik,β1,
σ2|D), is
nik∏
j=1
1√
2piσ2
exp
{
−
[
yikj − x⊤1ik(tikj)β1 − z⊤1ik(tikj)bik
]2
2σ2
}
, (9)
and the corresponding survival contribution, L2ik(bik,β2,γ, Qk|D), is
hik(Tik|bik,β2,γ, Qk)δik × exp
{
−
∫ Tik
0
hik(s|bik,β2,γ, Qk)ds
}
, (10)
where hik(·) is the hazard function (5). Consequently, the likelihood of the spatial joint
model (6)-(7) is the product of all N individual contributions to the likelihood:
L(θ|D) =
K∏
k=1
nk∏
i=1
Lik(θ|D) =
K∏
k=1
nk∏
i=1
L1ik(bik,β1, σ
2|D)× L2ik(bik,β2,γ, Qk|D). (11)
For example, if bik = (b1ik, b2ik)
⊤, γ = (γ1, γ2)
⊤, x2ik(t) = x2ik ∀ t, z⊤1ik(t) bik = b1ik+b2ik t,
γ⊤Z2ik(t) bik = γ1b1ik+γ2b2ik, and a = 1 in Equation (5), corresponding to an exponential
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distribution, the likelihood (11) is expressed as∏K
k=1
∏nk
i=1
∏nik
j=1
1√
2piσ2
exp
{
− 1
2σ2
[
yikj − x⊤1ik(tikj)β1 − b1ik − b2iktikj
]2}×
×∏Kk=1∏nki=1 {exp[x⊤2ikβ2 + γ1b1ik + γ2b2ik +Qk]}δik ×
× exp
{
−∑Kk=1∑nki=1 Tik exp[x⊤2ikβ2 + γ1b1ik + γ2b2ik +Qk]} .
(12)
3.4 Bayesian approach
For a Bayesian approach of the spatial joint model (6)-(7), we added prior distributions for
all model parameters. In particular, for the longitudinal component we took, respectively,
multivariate normal, Np1(0,V∗1), and inverse gamma, IG(c1, d1), priors for the vector of
fixed effects, β1, and the measurement error variance, σ
2. For the survival component,
we designated normal priors for both β2 and γ, respectively denoted by Np2(0,V∗2) and
Np3(0,V∗3). A gamma prior distribution, G(c2, d2), for the Weibull shape parameter,
a, and an inverse Wishart prior, IWish(V ∗4 , κ), for the covariance matrix, Σ, of the
random effects, bik, with V
∗
4 representing a p× p positive definite matrix prespecified and
with κ degrees of freedom. In consonance with Guo and Carlin [6], we chose very low
precision (high variance) for these priors, including an inverse Wishart prior that is vague
but does provide at least some shrinkage of the random effects toward 0, ensuring good
identifiability of the main effects.
Concerning the spatial frailty, Qk, we incorporated that dependence by specifying an
intrinsic conditionally autoregressive (ICAR) prior proposed in [24], i.e. the prior on
Q = (Q1, . . . , QK) is specified as a set of K univariate full conditional distributions,
Qk|σ2Q ∼ ICAR(σ2Q), allowing us to deal with the risk’s spatial autocorrelation, capturing
the “local” extra-variability in the log-relative risk so that nearby regions will have more
similar risks [17] (structured effect). For the spatial frailties variance, σ2Q, we assigned an
inverse gamma prior, IG(c3, d3), similarly assumed with high variance.
Although the convenience of the ICAR prior, one may certainly employ independent
priors for each spatial random effect. For instance replacing Qk by Vk in (5) we may
consider an exchangeable normal prior, Vk|σ2V ∼ N (0, σ2V ), if independence across areal
units is a plausible assumption (unstructured effect). This specification is appropriate
if the covariates included in (5) account for all of the spatial structure, leaving Vk to
account for the “global” region heterogeneity. We can also allow for both structured and
unstructured random effects, however, it requires two random effects to be estimated for
each region, whereas only their sum is identifiable from the data. Another problem is
the decrease in algorithm performance because identifiability problems [17]. Discussion of
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these issues is given in [25].
The joint posterior distribution of the Bayesian hierarchical spatial joint model (6)-(7),
denoted by p(θ|D), is proportional to
L(θ|D)× pi(β1|V∗1)× pi(β2|V∗2)×
∏K
k=1
∏nk
i=1 pi(bik|Σ)×
∏K
k=1 pi(Qk|σ2Q)×
×pi(γ|V∗3)× pi(Σ|V ∗4 , κ)× pi(σ2|c1, d1)× pi(a|c2, d2)× pi(σ2Q|c3, d3),
(13)
where L(θ|D) is defined in (11) and pi(·|·) generically denotes a prior distribution spec-
ified in the previous paragraphs. Typically, the marginal posterior distributions cannot
be carried out in closed form and, therefore, to avoid the analytic intractable integral
problem involved in the marginalized functions, we propose to apply MCMC methods in
OpenBUGS ([26]).
4 Model assessment
Due to recent computational advances, sophisticated techniques for Bayesian model as-
sessment are becoming increasingly popular (see some summary in [12, 17, 27]). The next
two Subsections are devoted to two of those techniques in a joint models context. First,
the prediction of future values and then a residual analysis.
4.1 Prediction of future values
The ability to incorporate the trajectory of the longitudinal biomarker over time in a
survival model gives to joint models the possibility to act as a dynamic prognostic tool,
which can drive to a more accurate clinical decision. For example, the full history of
CD4 counts observed in a patient with HIV/AIDS can be used to predict his survival
probability in the coming years, from the time of the last visit or after censoring. If the
CD4 trajectory indicates an increasing risk of death, the physician may decide to change
the therapy in order to slow the progression of the disease.
Proust-Lima and Taylor [7] proposed a dynamic prognostic tool for joint models provid-
ing a measure of variability obtained from the parameters asymptotic distribution and
validating this prognostic tool based on predictive accuracy measures. Rizopoulos [28]
focused particularly on the assessment of the predictive ability of the longitudinal out-
come for the survival outcome, assessing how well the former is capable of discriminating
between subjects who will experience or not the event within a certain period. Sweeting
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and Thompson [29] have compared shared random effects models with two approximation-
based approaches, concluding that these latter should be avoided since they can severely
underestimate any association between the longitudinal and event processes.
Suppose we have a series of repeated measurements from a new individual, along with its
survival information up to time t. Let D˜ = {y˜, T˜ = t, δ˜=0} be the summarized data for
this individual. Inferences on a future longitudinal value for this individual at time s > t,
denoted by y˜(s), can be obtained from its posterior predictive distribution conditional on
the existing data, D, and the new data, D˜ [7, 28, 29],
p(y˜(s) | D, D˜) =
∫∫
p(y˜(s)|D˜, b˜,θ) p(b˜|D˜,θ) p(θ|D)dθ db˜, (14)
where b˜ represents the random effects vector of the new individual, p(b˜|D˜,θ) is here
the posterior distribution of the new random effects and p(θ|D) is the joint posterior
distribution defined in (13). Similarly, the posterior predictive probability for the time-
to-event, T˜ ∗, of the new individual at time s given survival up to time t, is expressed
as
p(T˜ ∗ > s | D, T˜ ∗ > t, y˜) =
∫∫
S˜(s | y˜, b˜)
S˜(t | y˜, b˜) p(b˜|D˜,θ) p(θ|D) dθ db˜, (15)
where S˜(· | y˜, b˜) is the survival function for the new individual [7, 28, 29].
4.2 Residual analysis
Because model selection measures provide no information about the absolute adequacy of
the models, other diagnostic tools (e.g. residuals analysis) are needed to assess the model
adequacy. In checking model assumptions via the inspection of residuals, Dobson and
Henderson [30] pointed out some properties of the residuals conditioned by the dropout
information and Zhu et al. [31] developed a series of influence measures to quantify the
degree of perturbation introduced into the model during a sensitivity analysis. Recently,
for longitudinal and survival joint models Zhang et al. [32] developed a novel decomposi-
tion of the well-known model selection criteria AIC and BIC in order to assess the fit of
each component of the joint model, whereas Park and Qiu [33] discussed several model
selection criteria applying them to the joint model for comparing two crossing hazard
rate functions proposing hypothesis testing and graphical methods for model diagnostics.
Rizopoulos et al. [34] discussed the difficulty in using standard model diagnostics in joint
models because of the nonrandom dropout in the longitudinal outcome caused by the
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occurrence of events proposing a multiple-imputation-based approach as diagnostic and
model-assessment tool.
For the residual analysis of the survival component of the spatial joint model (6)-(7),
we can employ Cox-Snell residuals [35] by using the well-known relationship rCSik (t|θ) ≡∫ t
0
hik(s|θ)ds = − log Sik(t|θ). Conforming to Rizopoulos and Ghosh [36], we get rCSik (t)
calculating the expected value for rCSik (t|θ) averaged over the parameters posterior distri-
bution, p(θ|D), i.e.
rCSik (t) = Eθ|D
[
rCSik (t|θ)
]
=
∫
rCSik (t|θ) p(θ|D)dθ. (16)
In practice, we compute rCSik (t) at the observed event times Tik, being censored if the
event of interest did not occur for the related individuals. In order to check the fit of
the survival model taking into account the censoring times, we can graphically compare
the associated Kaplan–Meier estimate for rCSik (Tik) with the survival function of the unit
exponential distribution [36].
Regarding the residual analysis for the longitudinal component of the joint model, we
can make use of the widely used standardized marginal and standardized subject-specific
residuals for mixed models [37], respectively defined by
rymik = Vˆ
− 1
2
ik
[
yik −X1ikβˆ1
]
and rysik = σˆ
−1
[
yik −X1ikβˆ1 − Z1ikbˆik
]
, (17)
where βˆ1, σˆ, bˆik and Vˆik are posterior estimates (e.g. mean or median), respectively, for
the vector of regression coefficients β1, the residual standard deviation σ, the vector of
the random effects bik and the covariance matrix of the repeated measurements yik, i.e.,
Vik = Z1ikΣZ
⊤
1ik+σ
2I, with I denoting the identity matrix of appropriate dimensions, and
X1ik and Z1ik are design matrices whose rows are, respectively, x
⊤
1ik(tikj) and z
⊤
1ik(tikj).
Rizopoulos et al. [34] pointed out some issues in using the residuals (17) in joint models,
especially because the occurrence of events causes a nonrandom dropout in the longitu-
dinal outcome. Accordingly, they proposed to augment the observed longitudinal data
with a multiple-imputation-based scheme, under the assumed joint model. The main ad-
vantage of using both the augmented and observed data is to calculate residuals, such as
(17), that inherit now the properties of the complete data model and, therefore, they can
be directly used in diagnostic plots without requiring to take dropout into account.
Let ymik = {yik(tikj) ≡ yikj : tikj ≥ Tik, j=1, . . . , n′ik} be the missing part of the longitu-
dinal response vector, where n′ik is the total of augmented measurements concerning the
ikth individual. The multiple-imputation-based method consists of sampling from the
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posterior predictive distribution of ymik
p(ymik | D) =
∫
p(ymik|θ) p(θ|D)dθ. (18)
Notice that (i) we are assuming that ymik and D are independent, conditionally on θ; (ii)
the predicted ymik and observed yik values form the complete longitudinal data.
If the visiting times, tikj, of the repeated measurements are determined by the patients
themselves, we should model that random visiting process before obtaining the multiple-
imputation-based residuals (Rizopoulos et al. [34]). Let uikq denote the time elapsed
between (q−1)th and qth visits for the ikth subject with nik measures/visits, q=2, . . . , nik.
Assuming that all subjects have at least one measurement and the visiting process is non-
informative, we can let the distribution of the elapsed time, uikq, to depend only on the
last observed longitudinal measurement, i.e., p(uikq|yik(q−1);θv), where θv is the vector of
the visiting process parameters and tikq = tik(q−1)+uikq (see [34] for different formulations
of the visiting process and for a comprehensive simulation scheme of the elapsed times).
We propose to model the elapsed times vector, uik = (uik2, . . . , uiknik)
⊤, by using a Weibull
model, W(av, λv), with individual and spatial frailties expressed in terms of its hazard
function
hv(uikq|xvik,θv) = avuav−1ikq exp(x⊤vikβv +Qk)ωik, (19)
where βv is the vector of regression coefficients associated with the design vector xvik
containing possibly a functional form of the last observed longitudinal response, yik(q−1);
ωik is an individual frailty taking a gamma distribution, G(η, η), and Qk is a spatial
frailty as in (5). We note that in Rizopoulos et al. [34] there is not a spatial frailty in the
visiting process definition. In order to obtain the estimates of the various elapsed times,
we propose to resort to the posterior distribution of θv given all the visit data, Dv,
p(θv | Dv) ∝
K∏
k=1
nik∏
i=1
Lvik(θv|uik,xvik)× pi(θv)
=
K∏
k=1
nik∏
i=1
nik∏
q=2
{[hv(uikq|xvik,θv)] [Sv(uikq|xvik,θv)]} × pi(θv), (20)
where Lvik(.|.) is the ikth individual contribution to the likelihood, Sv(.) is the Weibull
survival function and pi(θv) is the prior distribution on θv. Then we carry on using the
posterior distribution, p(θv|Dv), to simulate the future elapsed times, uikq, q = nik+q′,
q′=1, . . . , n′ik, from its posterior predictive distribution
p(uikq | Dv) =
∫
p(uikq|θv) p(θv|Dv) dθv, (21)
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in order to get the missing ymikq’s at times tikq = tik(q−1)+uikq, q = nik+n
′
ik, q
′ = 1, . . . , n′ik,
via its predictive distribution (18). Along with the observed data, yik, we calculate the
residuals (17) for the complete longitudinal data of the spatial joint model (6)-(7).
5 Analysis of the HIV/AIDS data
5.1 Spatial joint model
The HIV/AIDS data described used in this work have well-defined spatial boundaries
associated with the residence geographic regions (Brazilian states) which is a typical
example of areal or lattice data. In addition, we believe that there exists a “neighborhood
effect”, where region’s risk-of-death is similar to that of neighboring locations, and also a
“grouping effect”, where subjects living in the same region are assumed to have identical
risk. The methodology developed in Section 3 is now applied to the HIV/AIDS data
described in Section 2. Based on exploratory analysis partially introduced in Section 2,
we assumed a square root transformation of the longitudinal measures (i.e.
√
CD4), as
well as the particular case (a = 1) of the Weibull survival model (exponential survival
model). Those practical considerations are in agreement with other AIDS joint analysis,
such as Guo and Carlin [6].
Let yikj denote the square root of the jth CD4 count measurement on the ith patient
living in the kth Brazilian state, j = 1, . . . , nik, whereas (Tik, δik) represents both the
AIDS survival time and the death indicator of the patient, i = 1, . . . , nk, k = 1, . . . , 27.
Several spatial joint models were fitted. For the longitudinal measures, an individual
polynomial trajectory inside the random effects model was considered to account for
patient-specific
√
CD4 counts over time (see e.g. Wu and Zhang [38] for some discussion
on polynomial mixed-effects models for longitudinal data). Particularly, we assumed
yikj|bik,β1, σ2 ∼ N (y∗ikj, σ2), where y∗ikj = µik(tikj) +Wik(tikj), and
µik(tikj)=β11 + β12tikj + β13t
2
ikj + β14t
3
ikj + β15genderik + β16ageik + β17PrevOIik
Wik(tikj)=b1ik + b2iktikj + b3ikt
2
ikj + b4ikt
3
ikj.
(22)
In regard to the survival times, we assumed T ∗ik|bik,β2, Qk ∼ W(1, λik(t)) ≡ E(λik(t)),
where
log(λik(t)) = β21 + β22genderik + β23ageik + β24PrevOIik +
∑4
s=1γsbsik +Qk, (23)
being the latent parameters, bsik, s = 1, . . . , 4, random effects related to the intercept,
slope, curvature and rate of change of the curvature. Notice that the γs coefficients,
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s=1, . . . , 4, quantify the extent to which each of the random effects influences the hazard
of death. For example, γ3 = −0.5 means that an individual with a positive curvature will
have a negative association with the hazard function implying a lower risk of death.
For the parameters of the various fitted spatial joint models, we assumed vague but proper
prior distributions because we had little prior information about them. In particular, we
considered: β1 = (β11, β12, β13, β14, β15, β16, β17)
⊤ ∼ N7(0, 1000 I); β2 = (β21, β22, β23, β24)⊤
∼ N4(0, 1000 I); bik = (b1ik, b2ik, b3ik, b4ik)⊤ ∼ N4(0,Σ); Σ ∼ IWish(1000 I, κ); γs ∼
N (0, 100), s=1, . . . , 4. 0 and I denote the null vector and identity matrix of appropriate
dimensions, respectively, and κ = N/20 ≈ 233 as stated in Guo and Carlin [6] to ensure
good identifiability of the main effects; for the spatial structured random effects we use
the ICAR prior distribution, Qk|σ2Q ∼ ICAR(σ2Q).
In some scenarios assuming a Gamma prior for the precision (inverse of the variance) can
be problematic, because of its sensitivity to prior choices of the parameters causing it to be
inappropriately biased away from 0 [39]. For instance, if we want to allow for the possibility
of no within-individual variability or a negligible spatial dependence between areas this
prior should not be the way forward! Although in our dataset having an individual with
zero variance, σ2 = 0, is implausible, so in accordance we assume σ−2 ∼ G(0.01, 0.01).
Concerning the prior for the precision of the spatial structured frailties, σ−2Q , Kelsall and
Wakefield [40] circumvented the problem suggesting an alternative prior for the precision
parameter, σ−2Q ∼ G(0.5, 0.0005), expressing the prior belief that the spatial random effects
standard deviation is centered around 0.05 with a 1% prior probability of being smaller
than 0.01 or larger than 2.5.
Initial values for the parameters β1 and β2 were obtained by modeling the longitudinal
and survival data individually. The choice of the prior distributions for σ2, β1, β2, Σ
and σ2Q were motivated by their conjugacy, assuming that they are independent a priori.
The covariates gender, age and PrevOI were always included into both longitudinal and
survival components of the fitted spatial joint models. Estimates of the parameters were
obtained through MCMC simulation within the OpenBugs [26] (vide SuppMat Section
5), based on sampling chains of 100,000 iterations following the 20,000 iterations of “burn-
in” period. In order to eliminate autocorrelation among samples within the chains, we
selected every 50th iteration of the chains. A study of the trace and density plots of the
posterior distributions indicated no convergence problems concerning these samples.
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5.2 Model selection
There are several summary measures for model comparison and selection. Namely, we
choose the Deviance Information Criterion (DIC) (Spiegelhalter et al. [41]) and the so-
called Watanabe-Akaike Information Criterion (WAIC) (Watanabe [42] and Gelman et
al. [43]) which is a recent penalized likelihood-based measure. DIC and WAIC handle
Bayesian models of any degree of complexity and smaller values indicate a better ad-
justment. The computation of these measures is straightforward using MCMC methods
because it is particularly convenient to compute them from posterior samples.
Table 1 reports DIC and WAIC values for a variety of fitted joint models with different
forms for the latent processes, W (t), for the linking structure, g(W (t)), and for the spatial
random effect, Q. We noted some inability of our data to reliably identify both the shape
parameter, a, and the survival intercept, β21, in the model (23), exhibiting strong nega-
tive correlation between the two-parameter samples and strong positive autocorrelations
in their individual samples. That was already mentioned by Guo and Carlin [6]. Mean-
while, we fitted a few models from Table 1 including these two parameters, but increasing
both the thin and the number of iterations per chain. After one day running in a Quad
core desktop computer, the posterior mean of a was 1.04 being similar to consider the
exponential survival model.
Based on the model selection measures in Table 1, considering only the first ten rows,
(linear) models sharing both random effects (individual intercept and time trend) result in
the best scenario. Models IX and X, which extend models VII and VIII by introducing the
spatial frailty, exhibit better comparison measures values. That can suggest some latent
spatial effect in the HIV/AIDS data. Models XI-XVIII assume higher degree polynomial
functions in order to look for more flexible time trends, being extensions of the models
VIII, IX and X. The decreasing values of model selection measures for the current models
set indicate that
√
CD4 longitudinal profile is better captured by a non-linear trajectory,
especially for Models XIV and XVIII. The latter has the lowest DIC and WAIC values
among all joint models and therefore is the selected spatial joint model (6)-(7). Other joint
models were fitted, namely considering only unstructured spatial random effects, where
Vk’s are assumed to have an exchangeable Gaussian prior; and simultaneously considering
both structured and unstructured spatial heterogeneity (vide Subsection 3.2 and SuppMat
at Section 2). Despite the values of the summary measures for these models being very
close to the ones in Table 1 we note that they are always larger. Furthermore we can also
note that considering both Qk and Vk at the same time (SuppMat models XXV–XXX)
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has virtually no impact on DIC or WAIC (compared to models XIII–XVIII) which means
that Qk are accounting for virtually all the residual variation between the states.
For the selected joint model (Model XVIII), we present the posterior mean and the 95%
credibility interval (CI) for their parameters of interest in Table 2. Additionally, in order
to compare separate and joint HIV/AIDS data analysis, we include the corresponding
estimates for Model IV that was the best separate model i.e. g(W (t))=0 and for Model
XIV, which is the same as Model XVIII but without the spatial component, Qk. Notice
that, for Model XVIII, the (symmetric) covariance matrix, Σ, is presented in terms of its
components: σb11, σ
b
12, σ
b
13, σ
b
14, σ
b
22, σ
b
23, σ
b
24, σ
b
33, σ
b
34, and σ
b
44. Based on the posterior
estimates we conclude that: (i) gender, age and PrevOI have “significant” effect both in
the CD4 count mean and the relative risk of death; (ii) male patients have lower CD4
counts and higher death risk during the follow-up than female ones; (iii) both patients
aged above 50 and with previous opportunistic infectious disease at study entry have
lower CD4 counts and higher death risk than patients in the opposite category of each
group. Moreover, the posterior estimates of the parameters γ1, γ2, γ3 and γ4 provide
strong evidence of a negative (latent) association between the two components. In fact, as
these coefficients represent the strength of the influence that each longitudinal individual
random effect, bi, has on the survival time we can say that if the individual trajectory is
above the population mean trajectory, that individual will have a good survival prognostic.
In simple terms, if a particular bi with each of its elements being positive, i.e., bi =
(bi1 > 0, bi2 > 0, bi3 > 0, bi4 > 0), then his
√
CD4 longitudinal trajectory will be above
the population mean trajectory implying that his survival time will be greater than the
population survival mean because he has a lowering in the risk of death.
We also conclude that our joint model present improvements over the survival time when
compared with a separate modeling. To illustrate this we considered Model IV, Model
XVIII and two patients: (i) Patient 85 - male, 31 years old, without previous opportunis-
tic infection and censored time 1,645 days; (ii) Patient 105 - male, 29 years old, with
previous opportunistic infection and censored time 1,508 days. Figure 1 shows patient
105 with a relatively “good” CD4 trajectory (starts relatively low and then increases),
while Patient 85 has a “not so good” one (starts low and do not increase much). Joint
results substantially differ from the separate ones, increasing the posterior median sur-
vival time for Patient 105, and decreasing it for Patient 85. Moreover, the joint model
actually reverses separate models findings, in the sense that the patient with the “good”
CD4 trajectory is now predicted to survive much longer than the patient with the “bad”
trajectory. For the median survival times of the patients 105 and 85, we obtained esti-
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mates of roughly 39 and 15, respectively. One referee suggested to provide information on
the performance of this phenomenon by summarizing all the subjects studied, by means of
the percentage of subjects with this right “reverse pattern”when considering his/her CD4
trajectory. We conduct a series of simulations, whose results are summarized in SuppMat
Section 3.
Figure 2 shows two maps for the HIV/AIDS data by Brazilian states, representing the
posterior spatial mean risk (left) and posterior spatial relative risk (right) based on model
XVIII, respectively defined by λ¯k =
∑nk
i=1 λik/nk and exp(Qk), with λik and Qk as in
Equation (23), k=1, . . . , 27. For convenience, the posterior means of these state-specific
quantities were ordered according to the quintiles of their distributions. The Brazilian
states with higher HIV/AIDS spatial mean risk are located in North region (3 out of
7 states: Acre, Amazonas, Para´) and Northeast region (2 out of 9 states: Para´ıba,
Sergipe), being these states more distant from the most populous states in Brazil, espe-
cially the first set of states. It is interesting to note that when we are not considering the
covariates effects and only the unobserved spatial variation (map on the right) the colors
are reversed indicating an increasing spatial relative risk for the South region (3 states:
Parana´, Santa Catarina, Rio Grande do Sul), Central-West region (2 out of 4 states:
Goia´s, Mato Grosso do Sul) and North region (1 out 7 states: Acre). Apart from
the last, the first five states have moderate population density and economic growth and,
even expecting to have better Public Health conditions, they still have some latent risk
factors for HIV/AIDS issue. As reported by Teixeira et al. [44], AIDS epidemic in Brazil
was only found to be expanding in the North and Northeast regions, while declining in
the rest of the country, especially in the Southeast. Similar maps for models XXIV and
XIV can be found on SuppMat Figure 3 and Figure 4, respectively.
Finally, note (Figure 2 - right panel) that the values of Qk’s are in the range (log(0.98),
log(1.04)) = (−0.02, 0.04) suggesting that missing regional covariates have nearly a null
impact (around to 2% to 4%) on the hazard. Such a small value suggests that covariates
like, for example, region economic status, quality of health care or population total per
region might not be needed in explaining the spatial epidemiology.
In order to investigate the influence of the spatial specification we carried out a sensitivity
analysis with respect to the hyperprior distribution for the spatial variance component,
σ2Q, of the selected model in Subsection 5.2, assuming several different inverse gamma
priors [45]. Change the distribution of the spatial variance, σ2Q, does not seem to affect
the value of the summary measures and therefore the selected model should not change
with that variation (see SuppMat – Section 1).
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5.3 Residual analysis
To assess Model XVIII, we employed residual analysis as presented in Subsection 4.2. For
the survival outcome the posterior estimates of the Cox-Snell residuals (16) were analyzed.
To be easier to understand we plotted the Kaplan–Meier curve for the posterior mean
of the Cox-Snell residuals (thick line) in Figure 3 (bottom panel), along with the unit
exponential distribution (thin line), corresponding to a perfect fitting model. Although
there is some deviation at the middle of the curves, the majority of the estimates are close
to the “perfect” survival curve. Actually, this deviation represents only a small percentage
of the total observations, about 7% of the sample size. Further examination reveals
that most of these observations correspond to individuals with only one CD4 measure.
Therefore, considering again that most individuals have two or more CD4 measurements,
model adequacy may be deemed reasonable.
Concerning the longitudinal outcome, we combined the standardized marginal and subject-
specific residuals (17) with the multiple-imputation-based residual approach (18). To
generate the random visiting process, we consider the Weibull model (19), whose hazard
function hv(uikq|xvik,θv) is given by
avu
av−1
ikq exp(βv0 + βv1ageik + βv2genderik + βv3PrevOIik + βv4 yik(q−1) +Qk)ωik. (24)
We assigned vague prior distributions to the regression coefficients, βvs, s = 0, . . . , 4,
to the Weibull shape parameter, av, and to the individual frailty, ωik. Namely, each
βvs ∼ N (0, 1000), av ∼ G(0.01, 0.01) and ωik ∼ G(0.01, 0.01). As mentioned before
σ2Q ∼ IG(0.5, 0.0005).
Aiming to get an easier reading of the residual analysis of the longitudinal component,
we produce plots of the corresponding residuals using L = 5 imputations and check for
systematic trends using weighted loess fits, with weight one for the observed residuals,
and 1/L for the imputed ones (see Rizopoulos et al. [34]). The plot of the standardized
subject-specific residuals in Figure 3 (left top panel) shows a slight but systematic growing
for the observed residuals (dark gray line). That behavior is alleviated when we consider
the imputed residuals (light gray line) and, therefore, the homoscedasticity of the errors
eikj is verified. In Figure 3 (right top panel), the plot of the standardized marginal
residuals point out that the fitted weighted loess curve, based on the observed data alone
versus the fitted values of
√
CD4, shows a slight systematic decrease (dark gray line)
but that behavior is not present when we look to the imputed residuals (light gray line),
indicating that after taking dropout into account the fitted joint model seems to be a
plausible model for this data set.
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Finally, the little differences observed between the dark gray and the light gray lines may
be due to the visits frequency of our follow-up. In a CD4 counts context Geskus R. [46]
shows that if follow-up is frequent the nonrandom dropout may not be a source of bias.
5.4 Prediction of future values
We performed predictions among patients in HIV/AIDS data as stated in Subsection 4.1,
for 11 individuals who died and had 6 or more CD4 repeated measures. We aimed to
obtain the conditional probability of surviving for some time later relatively to the last
CD4 measurement time considering that the individual was censored immediately after
it, in order to verify the time-to-event predictive ability of the model. In this sense, we
have removed these 11 individuals from the data before obtaining its posterior quantities.
Predictions were made such that each individual presented 20 CD4 measurements. Figure
4 shows plots with the two types of predictions: (i) CD4 median trajectory obtained
accordingly to (14) (dashed line) and its 95% CI (gray area); (ii) conditional survival
probability (solid line) obtained accordingly to (15).
Generally subjects are predicted to live longer than what occurred in reality. This can be
justified by the small percentage of death in the data, resulting in a shrinkage of these
individuals towards the overall mean of the survival time. For individuals with the lowest
CD4 counts, after 1 or 2 years the predictions are very inaccurate because the 95% CI for
the CD4 counts is very large (e.g. individuals 242 and 329). We note that what seems
to have the most influence on survival time prediction is the overall time trend. When
there is an upward trajectory, the survival curve remains almost constant and equal to 1
(e.g. individuals 329, 767, 1349 and 1415). The longitudinal component of the selected
model seems to capture the variations in the longitudinal trajectory because the most
part of the observations lies within the 95% CI (gray area). It should be noted that the
patients who died were not necessarily those ones with the worst CD4 trajectory, i.e.,
a decreasing overall slope in that trajectory. Possibly this caused some difficulties in
performing predictions.
We also run a few more simulations, namely to compare the longitudinal predictive per-
formance of our model XVIII against the separated model IV, the simple joint model IX
and two other models without and with unstructured spatial random effects, models XIV
and XXIV, respectively (vide SuppMat Section 4). Model XVIII always outperforms its
competitors in terms of coverage.
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6 Concluding remarks
The introduction of functional time and spatial frailty effects in longitudinal and survival
joint models adds new tools for analyzing them. The associated maps provide visual
representations of the regions in study, allowing to identify areas of high spatial relative
risk that should receive more attention and resource from the public health policy. From
this point of view it is of a great value to know that apparently there are no spatial
differences in the risk of death. It means that patients across all regions have e.g. access
to different health cares and their survival depends on the region where they live.
For our HIV/AIDS data, i)
√
CD4 longitudinal profile is better captured by a non-linear
trajectory; ii) joint analysis substantially differs from the separate ones, increasing (de-
creasing) the posterior median of the survival times for patients with a relatively “good”
(“not so good”) CD4 trajectory; iii) gender, age and PrevOI have “significant” effect both
in the CD4 count mean and the relative risk of death, for instance, male patients have
lower CD4 counts and higher death risk during the follow-up than female ones; iv) for the
prediction of future values, we note that the overall time trend seems to have the most
influence on survival time prediction and the patients who died were not necessarily those
ones with the worst CD4 trajectory.
In addition, the Brazilian states with higher HIV/AIDS spatial mean risk are located
in North region (Acre, Amazonas, Para´) and Northeast region (Para´ıba, Sergipe), being
these states more distant from the most populous states in Brazil. Although we have
found small spatial unobserved heterogeneity at state level in Brazil, taking into account
the spatial dependence structure improves the corresponding predictions of both the CD4
trajectory and the HIV/AIDS survival curve. (vide Subsection 5.4 and Sections 3 and 4
in SuppMat). In order to detect more spatial extra-variation in the Brazilian HIV/AIDS
data, we should have used another area definition instead of states which, unfortunately,
was not available in the database that has been provided.
Some of the posterior estimates from the non-spatial separate model IV, non-spatial joint
model XIV and the selected one (XVIII) are similar (Table 2). This could hide the
advantages in use the spatial model, but there are indeed important issues associated with
the proposed model and its results. For instance, i) some apparent overall stabilization
of the AIDS epidemic in Brazil tends to mask regional disparities and the susceptibility
of given specific locations and should, thus, be evaluated carefully through analyses with
lower levels of aggregation such as municipalities and micro-regions instead of states [44];
ii) motivated by the absence of past AIDS studies or expert conjectures in Brazil, we have
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used non-informative prior for spatial variance components. That assumption is well-
accept with a prior sensitivity analysis but not consensual, e.g. Gelman [39] discussed prior
distributions for variance parameters in hierarchical models illustrating some problems
with the inverse-gamma family of non-informative prior distributions.
With more biomedical studies taking measures of various outcomes over time in an effort
to evaluate a patient’s health or risk to some event, a joint modeling approach is indeed
useful to link these longitudinal and survival outcomes. Despite the reasonable ease of
implementing Bayesian joint models, they have some potential limitations, for example,
slow convergence of MCMC methods due to the large number of parameters that need
to be estimated. Alternative methods are the integrated nested Laplace approximation
methods (INLA), proposed by Rue et al. [47], which is a recent approach to statistical
inference based on latent Gaussian Markov random field models.
There is an undeniable appeal in applying joint models, but there is still a long way to
address issues such as identification of the appropriate association structure [48, 49]. Joint
models are on the front line of the statistical methods applied to a personalized medicine
mainly because of its ability in deriving individualized predictions both in the longitudinal
and survival responses, such the ones in Subsection 5.4.
AIDS is regarded today as a chronic disease. Indeed, because of the small percentage of
death in our database we could investigate a possible cure fraction in HIV/AIDS Brazilian
population, especially in Southwest region. It would be interesting to include other longi-
tudinal measures along with CD4 counts (e.g. viral load), thus generating a multivariate
longitudinal component of the spatial joint model.
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Table 1: Candidate Bayesian joint models for the HIV/AIDS data analysis.
Model W (t) g(W (t)) Q DIC WAIC
Part I - None or one degree polynomial function:
no random effects
I 0 0 0 139004 215495
random intercept
II b1 0 0 119686 196486
III b1 γ1b1 0 119359 195970
random intercept and random slope
IV b1 + b2t 0 0 112251 189537
V b1 + b2t γ1b1 0 112026 189069
VI b1 + b2t γ2b2 0 112228 189433
VII b1 + b2t γ(b1 + b2) 0 111948 188984
VIII b1 + b2t γ1b1 + γ2b2 0 111907 188863
spatial random effects
IX b1 + b2t γ1b1 + γ2b2 Q 111891 188883
X b1 + b2t γ(b1 + b2) Q 111952 188960
Part II - Two or more degree polynomial function:
no spatial random effects
XI b1 + b2t+ b3t2 γ1b1 + γ2b2 + γ3b3 0 108992 185051
XII b1 + b2t+ b3t2 + b4t3 γ1b1 + γ2b2 0 108483 184680
XIII b1 + b2t+ b3t2 + b4t3 γ1b1 + γ2b2 + γ3b3 0 108372 184492
XIV b1 + b2t+ b3t2 + b4t3 γ1b1 + γ2b2 + γ3b3 + γ4b4 0 108100 183649
spatial random effects
XV b1 + b2t+ b3t2 γ1b1 + γ2b2 + γ3b3 Q 108983 185005
XVI b1 + b2t+ b3t2 + b4t3 γ1b1 + γ2b2 Q 108475 184703
XVII b1 + b2t+ b3t2 + b4t3 γ1b1 + γ2b2 + γ3b3 Q 108388 184555
XVIII b1 + b2t+ b3t2 + b4t3 γ1b1 + γ2b2 + γ3b3 + γ4b4 Q 108083 183568
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Table 2: Posterior parameters estimates for separate (IV) and joint (XIV and XVIII)
models.
Model IV Model XIV Model XVIII
Parameter Mean 95% CI Mean 95% CI Mean 95% CI
Longitudinal:
Intercept (β11) 17.39 (17.14, 17.66) 16.93 (16.66, 17.2) 16.94 (16.66, 17.21)
Time (β12) 1.81 (1.71, 1.90) 4.26 (4.01, 4.52) 4.27 (4.01, 4.53)
Time2(β13) − − −1.68 (−1.85,−1.51) −1.68 (−1.87,−1.51)
Time3(β14) − − 0.24 (0.20, 0.28) 0.24 (0.20, 0.28)
Gender (β15) −0.63 (−0.93,−0.32) −0.64 (−0.93,−0.35) −0.65 (−0.93,−0.36)
Age (β16) −0.51 (−0.96,−0.05) −0.59 (−1.0,−0.14) −0.59 (−1.05,−0.14)
PrevOI (β17) −2.01 (−2.33,−1.71) −2.01 (−2.32,−1.70) −2.01 (−2.32− 1.72)
σ2 7.04 (6.87, 7.20) 5.48 (5.33, 5.64) 5.47 (5.32, 5.63)
σb
11
26.92 (25.64, 28.21) 30.45 (29.02, 31.93) 30.44 (29.01, 31.93)
σb
12
−4.72 (−5.28,−4.14) −13.56 (−15.34,−11.9) −13.55 (−15.29,−11.82)
σb
13
− − 3.89 (2.88, 4.98) 3.85 (2.78, 4.94)
σb
14
− − −0.25 (−0.47,−0.03) −0.23 (−0.46, 0.01)
σb
22
5.20 (4.82, 5.59) 25.10 (21.9, 28.73) 25.42 (22.13, 28.32)
σb
23
− − −8.20 (−10.19,−6.48) −8.38 (−9.94,−6.61)
σb
24
− − 0.71 (0.41, 1.07) 0.74 (0.43, 1.02)
σb
33
− − 3.19 (2.38, 4.23) 3.29 (2.42, 4.10)
σb
34
− − −0.34 (−0.50,−0.21) −0.35 (−0.48,−0.22)
σb
44
− − 0.15 (0.12, 0.16) 0.14 (0.12, 0.16)
Survival:
Intercept(β21) −4.30 (−4.54,−4.07) −5.91 (−6.37,−5.47) −5.90 (−6.40,−5.44)
Gender (β22) 0.33 (0.10, 0.59) 0.48 (0.17, 0.79) 0.47 (0.18, 0.78)
Age (β23) 0.62 (0.33, 0.88) 0.88 (0.53, 1.25) 0.87 (0.51, 1.23)
PrevOI (β24) 0.87 (0.63, 1.10) 1.09 (0.82, 1.38) 1.09 (0.81, 1.39)
γ1 − − −0.21 (−0.25,−0.17) −0.21 (−0.24,−0.17)
γ2 − − −0.46 (−0.61,−0.32) −0.45 (−0.58,−0.30)
γ3 − − −1.57 (−2.05,−1.13) −1.55 (−1.95,−1.08)
γ4 − − −5.95 (−6.84,−5.08) −5.94 (−6.88,−5.02)
σ2Q − − − − 0.014 (0.001, 0.120)
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Figure 1: CD4 trajectory for patients 85 and 105 (left) and the posterior distributions of
the median survival time for the patients 85 (middle) and 105 (right) using model XVIII
(solid line) and model IV (dashed line).
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Figure 2: Maps of the spatial mean (left) and relative (right) risks based on model XVIII.
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Figure 3: Standardized subject-specific (top left) and standardized marginal (top right)
residuals (black circles), augmented with all the multiply imputed residuals produced by
the L = 5 imputations (gray points). The superimposed dark gray and light gray lines
represent a loess fit based only on the observed residuals and a weighted loess fit based
on all residuals, respectively. The empirical survival curves (bottom panel) based on
the Kaplan-Meier posterior estimates of the Cox-Snell residuals (thick line) and the unit
exponential distribution (thin line).
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Figure 4: Predictions of the
√
CD4 trajectory and the survival curve for 11 patients
(first eleven panels) and all patients (bottom right panel) based on model XVIII. Median√
CD4 trajectory (dashed line) and predicted survival curve (solid line) after last CD4
measurement. Gray area delimits the 95% CI, whereas vertical line is the observed survival
time for each patient.
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